Stay updated on Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial page.

Latest updates to the Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial page
- Check3 days agoChange DetectedThe page indicates a minor version update from v3.3.3 to v3.3.4 with no apparent changes to study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedThe Contacts and Locations section was updated to add multiple new sites across the US (including California, Colorado, Connecticut, Florida, Illinois, Indiana, Kansas, Maryland, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New York, Ohio, Oregon, Pennsylvania, Utah) and a location in Vienne, while removing several existing entries; this reflects updated site availability and contact points for potential participants.SummaryDifference1%

- Check53 days agoChange DetectedPubMed publications note updated to indicate automatic filling from PubMed and Revision: v3.3.2; the previous PubMed note and Revision: v3.2.0 were removed.SummaryDifference0.1%

- Check60 days agoChange DetectedThe funding-status notice at the top of the page was removed; this does not affect the study details or eligibility information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check74 days agoChange DetectedNo additions or deletions were detected; the page content appears unchanged.SummaryDifference0.2%

- Check81 days agoChange DetectedAdded a new field labeled 'Last Update Posted (Estimated)' on the Study Details page and removed the previous 'Last Update Posted' field.SummaryDifference0.0%

Stay in the know with updates to Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab/Daratumumab in Multiple Myeloma Clinical Trial page.